Vaccine selection brings products closer to clinical trials slated to begin as early as this winter
Today, the U.S. Department of Health and Human Services , through the Administration for Strategic Preparedness and Response , is announcing the selection of initial next-generation vaccine candidates and more than $500 million in awards for Project NextGen – kick-starting planning for Phase 2b clinical trials and technologies that advance innovative next-generation vaccine and therapeutics platforms.
“The Biden-Harris Administration is committed to keeping people safe from COVID-19,” said HHS Secretary Xavier Becerra. “By investing in next-generation vaccines and treatments, we can improve our ability to respond to new variants, reduce transmission, stop infections, and save lives. Through Project NextGen, we are combining research and development expertise at HHS with the lessons learned throughout the pandemic to protect our nation from COVID-19.
“The vaccine selections and funding announced today are important steps forward for Project NextGen – with vaccine and therapeutics candidates moving quickly to clinical trials that will start in the coming months,” said Assistant Secretary for Preparedness and Response Dawn O’Connell. “The technologies that BARDA is investing in, from intranasal vaccines to self-amplifying mRNA, will bolster our protection against COVID-19 for years to come.
All three next-generation vaccine selections announced today are distinct from each other, targeting stronger, broader, or longer-lasting immune responses. Intranasal vaccines have the potential to stop viruses at the site of infection and self-amplifying mRNA and additional antigens may generate a stronger immune response than current vaccine technologies.
Finally, BARDA is awarding over $241 million to support new technologies that will improve national preparedness for future COVID-19 outbreaks and patient access. These technologies have the potential to enable shorter development timelines for monoclonal antibodies through mRNA, increased efficiency in virus testing, and alternate routes for vaccine administration:to Vir Biotechnology to support the development of mRNA-expressed monoclonal antibodies.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Disney Selects Two Directors For Its Unscripted Directing ProgramDisney Entertainment Television is expanding its Directing Program into the unscripted genre for the first time, selecting two directors for its inaugural run. The program will offer emerging direc…
Weiterlesen »
Biden selects 7 hydrogen hubs across 16 states for $7 billion in U.S. grantsPresident Joe Biden is announcing the recipients of $7 billion in federal grants for development of regional hydrogen hubs in 16 states.
Weiterlesen »
The most influential crowdsourcing project happened long before WikipediaThe Oxford English Dictionary relied on contributions by volunteers from around the world. “The Dictionary People,” by Sarah Ogilvie, tells the fascinating story.
Weiterlesen »
3 Project Management Strategies for a Hybrid WorkplaceOn a hybrid project, communication and coordination become both more critical and more challenging. Digital tools and meetings may be the only way some team members can keep in touch.
Weiterlesen »
The Rise of the Chief Project OfficerThirty years ago 80% of the resources in an organization were dedicated to operations, and 20% to projects; today, that ratio has flipped. Despite this massive disruption, most organizations still don’t have one senior leader overseeing or supervising all the project activities. A chief project officer (CPO) should fill that void.
Weiterlesen »